These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12717312)

  • 1. [Concomitant radiotherapy-chemotherapy for unresectable cancers of the head and neck: a retrospective analysis of 130 patients].
    Resche-Rigon P; Pignon T; Giovanni A; Gras R; Bagarry D; Zanaret M
    Ann Otolaryngol Chir Cervicofac; 2003 Feb; 120(1):3-13. PubMed ID: 12717312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
    Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
    BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent chemotherapy and "concomitant boost" radiotherapy for unresectable head and neck cancer.
    Teh BS; Monga U; Thornby J; Gressot L; Parke RB; Donovan DT
    Am J Otolaryngol; 2000; 21(5):306-11. PubMed ID: 11032294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
    Koiwai K; Shikama N; Sasaki S; Shinoda A; Kadoya M
    Jpn J Clin Oncol; 2009 Jul; 39(7):413-7. PubMed ID: 19383615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
    van den Broek GB; Rasch CR; Pameijer FA; Peter E; van den Brekel MW; Tan IB; Schornagel JH; de Bois JA; Zijp LJ; Balm AJ
    Cancer; 2004 Oct; 101(8):1809-17. PubMed ID: 15386309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous radio- and chemotherapy for squamous cell carcinoma of the head and neck in daily clinical practice: 5 years experience in a University Hospital.
    Langenberg M; Terhaard CH; Hordijk GJ; Es RJ; Voest EE; Graeff A
    Clin Otolaryngol Allied Sci; 2004 Dec; 29(6):729-34. PubMed ID: 15533169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
    Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
    J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma.
    Salas S; Deville JL; Giorgi R; Pignon T; Bagarry D; Barrau K; Zanaret M; Giovanni A; Bourgeois A; Favre R; Duffaud F
    Radiother Oncol; 2008 May; 87(2):195-200. PubMed ID: 18342966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
    Allal AS; Taussky D; Mach N; Becker M; Bieri S; Dulguerov P
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1431-6. PubMed ID: 15050320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated hyperfractionated irradiation with concomitant boost for stage II laryngeal cancer and locally advanced head and neck cancer.
    Ishii K; Tashiro M; Hosono M; Fukuda H; Takada Y; Kondo S; Inoue Y; Iguchi H; Kusuki M; Yamane H
    Acta Otolaryngol Suppl; 2004 Oct; (554):62-6. PubMed ID: 15513514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.
    Biagioli MC; Harvey M; Roman E; Raez LE; Wolfson AH; Mutyala S; Han HS; Markoe A
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1067-73. PubMed ID: 17967302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
    Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
    Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified radical neck dissection and minimal invasive tumor surgery in the middle of split course of concomitant chemoradiotherapy of advanced HNSCC.
    Schwentner I; Schmutzhard J; Andrle J; Haidenberger A; Thumfart WF; De Vries A; Sprinzl GM
    Auris Nasus Larynx; 2007 Mar; 34(1):85-9. PubMed ID: 17074457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations.
    Hanna E; Alexiou M; Morgan J; Badley J; Maddox AM; Penagaricano J; Fan CY; Breau R; Suen J
    Arch Otolaryngol Head Neck Surg; 2004 Jul; 130(7):861-7. PubMed ID: 15262764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.